Direct oral anticoagulants are the primary stroke prevention option in patients with atrial
fibrillation. Anticoagulant use before stroke, however, might inhibit clinician comfort with …

Ischemic stroke (IS) is a major cause of mortality and morbidity worldwide. Beyond
thrombolysis, strategies targeting anti-oxidative apoptosis and angiogenesis are considered …

Idarucizumab is an antibody fragment specific for the immediate reversal of dabigatran
anticoagulation effects. The use of idarucizumab is approved for dabigatran-treated patients …

Introduction Direct oral anticoagulants (DOACs) have been established as first-line therapy
for stroke prevention in patients with non-valvular atrial fibrillation due to their high safety …

Background and Objectives Limited data exist on the safety of IV thrombolysis (IVT) for acute
ischemic stroke (AIS) after dabigatran reversal with idarucizumab. We sought to evaluate the …

Background: For patients experiencing ischemic stroke despite receiving therapy with direct
oral anticoagulants (DOAC) and without endovascular treatment options, therapeutic …

Background As anticoagulants are widely used to treat patients with atrial fibrillation (AF)
and other thrombotic conditions, it is necessary for physicians to determine whether the …

The administration of intravenous thrombolysis (IVT) for patients with acute ischemic stroke
who have recently ingested direct oral anticoagulants (DOACs) presents a clinical challenge …

Background Evidence supports Cerebrolysin's efficacy in reducing hemorrhagic
transformation (HT), but its impact on the timing of resuming anticoagulation therapy in …